A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions
- PMID: 10049823
- DOI: 10.1006/viro.1998.9544
A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions
Abstract
A novel approach to complement human immunodeficiency virus type I (HIV-1) integrase (IN)-defective virions has been identified. The approach involves fusion of a 23-amino-acid stretch to the N-terminus of wild-type IN and coexpression of this chimera with the IN-defective proviral template in virus producing cells. The 23-amino-acid peptide represents a Vpr "interactor," referred to as the the WxxF or WF domain, which apparently leads to docking of the domain along with the fusion partner onto HIV-1 Vpr, thus permitting virion incorporation of the chimeric protein when expressed, in trans, with other viral products. Transfection of the WF-IN expression plasmid along with HIV-1 viral clones that produce Vpr, but bear an IN mutation, results in the release of a proportion of viral particles that are competent for integration. The extent of complementation was assessed using the MAGI cell assay, where integration of viral DNA results in the eventual appearance of easily visible multinucleated blue syncytia. The efficiency of dWF-IN (double copy of WF domain) complementation is not improved markedly by incorporation of a HIV-1 protease cleavage site (PR) between the dWF domain and IN (dWF-PR-IN), unlike that observed with Vpr fusions to IN. Furthermore, the ability of Vpr-PR-IN and dWF-PR-IN to complement IN-defective proviral clones, both of which bear an intervening protease cleavage site, appear comparable. Western blotting analyses using virions isolated through sucrose cushions demonstrate clearly the incorporation of the dWF-IN fusion protein into Vpr containing HIV-1 particles but not in Vpr-deficient virions. Additional Western blotting analyses indicate that all Vpr-IN and dWF-IN chimeras, with or without a PR site, are packaged into virions. The efficiency of virion incorporation of Vpr-IN and dWF-IN chimeras appears approximately comparable by Western blotting analysis. The ability of dWF-IN to complement IN-defective proviruses with efficiency similar to that of Vpr-PR-IN and dWF-PR-IN indicates that dWF-IN retains the full complement of functions necessary for integration of proviral DNA and is likely due to the benign nature of this small domain at the amino-terminus of IN.
Copyright 1999 Academic Press.
Similar articles
-
Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.Virology. 1996 May 1;219(1):307-13. doi: 10.1006/viro.1996.0253. Virology. 1996. PMID: 8623547
-
HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect.Gene Ther. 1999 Sep;6(9):1590-9. doi: 10.1038/sj.gt.3300988. Gene Ther. 1999. PMID: 10490769
-
Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.J Hum Virol. 2000 Jan-Feb;3(1):6-15. J Hum Virol. 2000. PMID: 10774802
-
HIV-1 viral protein R (Vpr) regulates viral replication and cellular proliferation in T cells and monocytoid cells in vitro.J Leukoc Biol. 1997 Jul;62(1):93-9. doi: 10.1002/jlb.62.1.93. J Leukoc Biol. 1997. PMID: 9225999 Review.
-
HIV-1 Vpr: genetic diversity and functional features from the perspective of structure.DNA Cell Biol. 2004 Apr;23(4):207-22. doi: 10.1089/104454904773819798. DNA Cell Biol. 2004. PMID: 15142378 Review.
Cited by
-
The HIV-1 protein Vpr targets the endoribonuclease Dicer for proteasomal degradation to boost macrophage infection.Virology. 2013 Sep;444(1-2):191-202. doi: 10.1016/j.virol.2013.06.010. Epub 2013 Jul 9. Virology. 2013. PMID: 23849790 Free PMC article.
-
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription.J Virol. 2000 Mar;74(6):2594-602. doi: 10.1128/jvi.74.6.2594-2602.2000. J Virol. 2000. PMID: 10684273 Free PMC article.
-
Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest.PLoS One. 2014 Feb 18;9(2):e89195. doi: 10.1371/journal.pone.0089195. eCollection 2014. PLoS One. 2014. PMID: 24558487 Free PMC article.
-
Driving DNA transposition by lentiviral protein transduction.Mob Genet Elements. 2014 Jun 23;4:e29591. doi: 10.4161/mge.29591. eCollection 2014. Mob Genet Elements. 2014. PMID: 25057443 Free PMC article.
-
Inhibition of HIV-1 Viral Infection by an Engineered CRISPR Csy4 RNA Endoribonuclease.PLoS One. 2015 Oct 23;10(10):e0141335. doi: 10.1371/journal.pone.0141335. eCollection 2015. PLoS One. 2015. PMID: 26495836 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials